格隆汇2月24日丨康方生物-B(9926.HK)涨逾4%,报55.3港元,总市值452亿港元。
康方生物公布,Cadonilimab(PD-1/CTLA-4双特异性抗体)获得美国FDA孤儿药资格认定,用于治疗宫颈癌。另外,派安普利单抗(PD-1)联合化疗一线治疗鳞状非小细胞肺癌的III期临床试验中期分析达到主要终点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.